Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

65 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effects of ezetimibe on cyclosporine pharmacokinetics in healthy subjects.
Bergman AJ, Burke J, Larson P, Johnson-Levonas AO, Reyderman L, Statkevich P, Kosoglou T, Greenberg HE, Kraft WK, Frick G, Murphy G, Gottesdiener K, Paolini JF. Bergman AJ, et al. Among authors: paolini jf. J Clin Pharmacol. 2006 Mar;46(3):321-7. doi: 10.1177/0091270005284851. J Clin Pharmacol. 2006. PMID: 16490808 Clinical Trial.
Bioequivalence of an ezetimibe/simvastatin combination tablet and coadministration of ezetimibe and simvastatin as separate tablets in healthy subjects.
Migoya EM, Bergman A, Hreniuk D, Matthews N, Yi B, Roadcap B, Valesky R, Liu L, Riffel K, Groff M, Zhao JJ, Musson DG, Gambale J, Kosoglou T, Statkevich P, Lasseter KC, Laurent A, Johnson-Levonas AO, Murphy G, Gottesdiener K, Paolini JF. Migoya EM, et al. Among authors: paolini jf. Int J Clin Pharmacol Ther. 2006 Feb;44(2):83-92. doi: 10.5414/cpp44083. Int J Clin Pharmacol Ther. 2006. PMID: 16502768 Clinical Trial.
Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression.
Lauring B, Taggart AK, Tata JR, Dunbar R, Caro L, Cheng K, Chin J, Colletti SL, Cote J, Khalilieh S, Liu J, Luo WL, Maclean AA, Peterson LB, Polis AB, Sirah W, Wu TJ, Liu X, Jin L, Wu K, Boatman PD, Semple G, Behan DP, Connolly DT, Lai E, Wagner JA, Wright SD, Cuffie C, Mitchel YB, Rader DJ, Paolini JF, Waters MG, Plump A. Lauring B, et al. Among authors: paolini jf. Sci Transl Med. 2012 Aug 22;4(148):148ra115. doi: 10.1126/scitranslmed.3003877. Sci Transl Med. 2012. PMID: 22914621 Clinical Trial.
Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease.
Maccubbin D, Koren MJ, Davidson M, Gavish D, Pasternak RC, Macdonell G, Mallick M, Sisk CM, Paolini JF, Mitchel Y. Maccubbin D, et al. Among authors: paolini jf. Am J Cardiol. 2009 Jul 1;104(1):74-81. doi: 10.1016/j.amjcard.2009.02.047. Am J Cardiol. 2009. PMID: 19576324 Clinical Trial.
Safety of extended-release niacin/laropiprant in patients with dyslipidemia.
McKenney J, Bays H, Koren M, Ballantyne CM, Paolini JF, Mitchel Y, Betteridge A, Kuznetsova O, Sapre A, Sisk CM, Maccubbin D. McKenney J, et al. Among authors: paolini jf. J Clin Lipidol. 2010 Mar-Apr;4(2):105-112.e1. doi: 10.1016/j.jacl.2010.02.002. Epub 2010 Feb 12. J Clin Lipidol. 2010. PMID: 21122637 Clinical Trial.
65 results